Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
No identifiable cause can be found in more than half of the cases of portal vein thrombosis (PVT). Our aim was to assess the prevalence of factor V Leiden mutation and other thrombophilic factors as risk factors in the development of PVT in the pediatric age group. From March 2001 to January 2002, 40 children with PVT were enrolled in the study, in addition to 20 age-matched and sex-matched controls. Protein C, protein S, antithrombin III, and activated protein C resistance (APCR) were assayed. Molecular study of factor II and factor V mutations was carried out. Of the patients, 25 had detectable hereditary thrombophilia (62.5%), 12 had factor V Leiden mutation (30%), 11 had protein C deficiency (27.5%), 6 had factor II mutation (15%), 1 had antithrombin III deficiency (2.5%), and none had protein S deficiency. Five children had concurrence of more than one defect. Factor V Leiden mutation is the most common hereditary thrombophilia associated with PVT and the relative risk of factor V Leiden mutation, as a cause of PVT, was six times more than in controls (odds ratio=6). Concurrence of more than one hereditary thrombophilic factor was seen in 12.5% of our patients. Circumstantial risk factors (neonatal sepsis, umbilical sepsis, umbilical catheterization) were not more significantly prevalent among patients with hereditary thrombophilia than among those with no detectable abnormalities in anticoagulation.
El-Karaksy
Hanaa
H
Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt. hanaakaraksy@hotmail.com
El-Koofy
Nehal
N
El-Hawary
Manal
M
Mostafa
Azza
A
Aziz
Mona
M
El-Shabrawi
Mortada
M
Mohsen
Nabil A
NA
Kotb
Magd
M
El-Raziky
Mona
M
El-Sonoon
Marwa Abu
MA
A-Kader
Hassan
H
D020016:Activated Protein C Resistance / Q000235:genetics; D000293:Adolescent; D000990:Antithrombin III / Q000235:genetics; D001798:Blood Proteins / Q000235:genetics*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004534:Egypt; D005165:Factor V / Q000235:genetics*; D005260:Female; D006579:Heterozygote; D006761:Hospitals; D006801:Humans; D007223:Infant; D008297:Male; D009154:Mutation / Q000235:genetics*; D011169:Portal Vein / Q000473:pathology*; D011486:Protein C / Q000235:genetics; D017293:Protein S / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D013927:Thrombosis / Q000453:epidemiology / Q000235:genetics*
D001798:Blood Proteins; D011486:Protein C; D017293:Protein S; D000990:Antithrombin III; D005165:Factor V; D011516:Prothrombin